US 2018/0022817 A1 · ANTI-CEACAM5 ANTIBODIES AND USES THEREOF

Abstract

The present invention discloses antibodies which bind human and Macaca fascicularis CEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also discloses immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.

Claims8

Dependent claims

1-39. (canceled)

An isolated nucleic acid comprising a sequence encoding an antibody or antigen binding fragment thereof wherein said antibody or antigen binding fragment thereof comprises

a) a CDR1-H comprising an amino acid sequence of SEQ ID NO:1;
a CDR2-H comprising an amino acid sequence of SEQ ID NO:2;
a CDR3-H comprising an amino acid sequence of SEQ ID NO:3;
a CDR1-L comprising an amino acid sequence of SEQ ID NO:4;
a CDR2-L comprising an amino acid sequence of SAS;
and a CDR3-L comprising an amino acid sequence of SEQ ID NO:6;
or
b) a CDR1-H comprising an amino acid sequence of SEQ ID NO:7;
a CDR2-H comprising an amino acid sequence of SEQ ID NO:8;
a CDR3-H comprising an amino acid sequence of SEQ ID NO:9;
a CDR1-L comprising an amino acid sequence of SEQ ID NO:10;
a CDR2-L comprising an amino acid sequence of NTK or NTR;
and a CDR3-L comprising an amino acid sequence of SEQ ID NO:12;
or
c) a CDR1-H comprising an amino acid sequence of SEQ ID NO:13;
a CDR2-H comprising an amino acid sequence of SEQ ID NO:14;
a CDR3-H comprising an amino acid sequence of SEQ ID NO:15;
a CDR1-L comprising an amino acid sequence of SEQ ID NO:16;
a CDR2-L comprising an amino acid sequence SAS;
and a CDR3-L comprising an amino acid sequence of—SEQ ID NO:18;
or
d) a CDR1-H comprising an amino acid sequence of SEQ ID NO:19;
a CDR2-H comprising an amino acid sequence of SEQ ID NO:20;
a CDR3-H comprising an amino acid sequence of SEQ ID NO:21;
a CDR1-L comprising an amino acid sequence of SEQ ID NO:22;
a CDR2-L comprising an amino acid sequence of NAK;
and a CDR3-L comprising an amino acid sequence of SEQ ID NO:24;
or
e) a CDR1-H comprising an amino acid sequence of SEQ ID NO:25;
a CDR2-H comprising an amino acid sequence of SEQ ID NO:26;
a CDR3-H comprising an amino acid sequence of SEQ ID NO:27;
a CDR1-L comprising an amino acid sequence of SEQ ID NO:28;
a CDR2-L of sequence NAK;
and a CDR3-L comprising an amino acid sequence of SEQ ID NO:30.

31 more elements

A method of treating a patient comprising administering to the patient an antibody or antigen binding fragment thereof which binds to human CEACAM5 protein, wherein the patient has a CEACAM5 expressing cancer and wherein the antibody or antigen binding fragment thereof comprises:

a) a CDR1-H comprising an amino acid sequence of SEQ ID NO:1;
a CDR2-H comprising an amino acid sequence of SEQ ID NO:2;
a CDR3-H comprising an amino acid sequence of SEQ ID NO:3;
a CDR1-L comprising an amino acid sequence of SEQ ID NO:4;
a CDR2-L comprising an amino acid sequence of SAS;
and a CDR3-L comprising an amino acid sequence of SEQ ID NO:6;
or
b) a CDR1-H comprising an amino acid sequence of SEQ ID NO:7;
a CDR2-H comprising an amino acid sequence of SEQ ID NO:8;
a CDR3-H comprising an amino acid sequence of SEQ ID NO:9;
a CDR1-L comprising an amino acid sequence of SEQ ID NO:10;
a CDR2-L comprising an amino acid sequence of NTK or NTR;
and a CDR3-L comprising an amino acid sequence of SEQ ID NO:12;
or
c) a CDR1-H comprising an amino acid sequence of SEQ ID NO:13;
a CDR2-H comprising an amino acid sequence of SEQ ID NO:14;
a CDR3-H comprising an amino acid sequence of SEQ ID NO:15;
a CDR1-L comprising an amino acid sequence of SEQ ID NO:16;
a CDR2-L comprising an amino acid sequence SAS;
and a CDR3-L comprising an amino acid sequence of—SEQ ID NO:18;
or
d) a CDR1-H comprising an amino acid sequence of SEQ ID NO:19;
a CDR2-H comprising an amino acid sequence of SEQ ID NO:20;
a CDR3-H comprising an amino acid sequence of SEQ ID NO:21;
a CDR1-L comprising an amino acid sequence of SEQ ID NO:22;
a CDR2-L comprising an amino acid sequence of NAK;
and a CDR3-L comprising an amino acid sequence of SEQ ID NO:24;
or
e) a CDR1-H comprising an amino acid sequence of SEQ ID NO:25;
a CDR2-H comprising an amino acid sequence of SEQ ID NO:26;
a CDR3-H comprising an amino acid sequence of SEQ ID NO:27;
a CDR1-L comprising an amino acid sequence of SEQ ID NO:28;
a CDR2-L of sequence NAK;
and a CDR3-L comprising an amino acid sequence of SEQ ID NO:30.

31 more elements

A method of treating a patient comprising administering an immunoconjugate to the patient, wherein the immunoconjugate comprises an antibody or antigen binding fragment thereof linked to at least one growth inhibitory agent, wherein the patient has a CEACAM5 expressing cancer, and wherein the antibody or antigen binding fragment thereof binds to human CEACAM5 protein and comprises:

a) a CDR1-H comprising an amino acid sequence of SEQ ID NO:1;
a CDR2-H comprising an amino acid sequence of SEQ ID NO:2;
a CDR3-H comprising an amino acid sequence of SEQ ID NO:3;
a CDR1-L comprising an amino acid sequence of SEQ ID NO:4;
a CDR2-L comprising an amino acid sequence of SAS;
and a CDR3-L comprising an amino acid sequence of SEQ ID NO:6;
or
b) a CDR1-H comprising an amino acid sequence of SEQ ID NO:7;
a CDR2-H comprising an amino acid sequence of SEQ ID NO:8;
a CDR3-H comprising an amino acid sequence of SEQ ID NO:9;
a CDR1-L comprising an amino acid sequence of SEQ ID NO:10, a CDR2-L comprising an amino acid sequence of NTK or NTR;
and a CDR3-L comprising an amino acid sequence of SEQ ID NO:12;
or
c) a CDR1-H comprising an amino acid sequence of SEQ ID NO:13;
a CDR2-H comprising an amino acid sequence of SEQ ID NO:14;
a CDR3-H comprising an amino acid sequence of SEQ ID NO:15;
a CDR1-L comprising an amino acid sequence of SEQ ID NO:16;
a CDR2-L comprising an amino acid sequence SAS;
and a CDR3-L comprising an amino acid sequence of—SEQ ID NO:18;
or
d) a CDR1-H comprising an amino acid sequence of SEQ ID NO:19;
a CDR2-H comprising an amino acid sequence of SEQ ID NO:20;
a CDR3-H comprising an amino acid sequence of SEQ ID NO:21;
a CDR1-L comprising an amino acid sequence of SEQ ID NO:22;
a CDR2-L comprising an amino acid sequence of NAK;
and a CDR3-L comprising an amino acid sequence of SEQ ID NO:24;
or
e) a CDR1-H comprising an amino acid sequence of SEQ ID NO:25;
a CDR2-H comprising an amino acid sequence of SEQ ID NO:26;
a CDR3-H comprising an amino acid sequence of SEQ ID NO:27;
a CDR1-L comprising an amino acid sequence of SEQ ID NO:28;
a CDR2-L of sequence NAK;
and a CDR3-L comprising an amino acid sequence of SEQ ID NO:30.

30 more elements

A method of detecting cancer in a patient comprising,

a) contacting a biological sample from the patient with an antibody or antigen binding fragment thereof which binds to human an CEACAM5 protein, wherein the patient has a CEACAM5 expressing cancer and wherein the antibody or antigen binding fragment thereof comprises:
i) a CDR1-H comprising an amino acid sequence of SEQ ID NO:1;
a CDR2-H comprising an amino acid sequence of SEQ ID NO:2;
a CDR3-H comprising an amino acid sequence of SEQ ID NO:3;
a CDR1-L comprising an amino acid sequence of SEQ ID NO:4;
a CDR2-L comprising an amino acid sequence of SAS;
and a CDR3-L comprising an amino acid sequence of SEQ ID NO:6;
or
ii) a CDR1-H comprising an amino acid sequence of SEQ ID NO:7;
a CDR2-H comprising an amino acid sequence of SEQ ID NO:8;
a CDR3-H comprising an amino acid sequence of SEQ ID NO:9;
a CDR1-L comprising an amino acid sequence of SEQ ID NO:10, a CDR2-L comprising an amino acid sequence of NTK or NTR;
and a CDR3-L comprising an amino acid sequence of SEQ ID NO:12;
or
iii) a CDR1-H comprising an amino acid sequence of SEQ ID NO:13;
a CDR2-H comprising an amino acid sequence of SEQ ID NO:14;
a CDR3-H comprising an amino acid sequence of SEQ ID NO:15;
a CDR1-L comprising an amino acid sequence of SEQ ID NO:16;
a CDR2-L comprising an amino acid sequence SAS;
and a CDR3-L comprising an amino acid sequence of—SEQ ID NO:18;
or
iv) a CDR1-H comprising an amino acid sequence of SEQ ID NO:19;
a CDR2-H comprising an amino acid sequence of SEQ ID NO:20;
a CDR3-H comprising an amino acid sequence of SEQ ID NO:21;
a CDR1-L comprising an amino acid sequence of SEQ ID NO:22;
a CDR2-L comprising an amino acid sequence of NAK;
and a CDR3-L comprising an amino acid sequence of SEQ ID NO:24;
or
v) a CDR1-H comprising an amino acid sequence of SEQ ID NO:25;
a CDR2-H comprising an amino acid sequence of SEQ ID NO:26;
a CDR3-H comprising an amino acid sequence of SEQ ID NO:27;
a CDR1-L comprising an amino acid sequence of SEQ ID NO:28;
a CDR2-L of sequence NAK;
and a CDR3-L comprising an amino acid sequence of SEQ ID NO:30;
b) measuring bound antibody or antigen binding fragment thereof to said biological sample;
and
c) detecting the cancer by comparing the bound antibody or antigen fragment thereof with a control, wherein an increased level of bound antibody or antigen binding fragment thereof compared to control being indicative of a cancer.

34 more elements

Dependencies are inferred from the claim text.

Anti-ceacam5 antibodies and uses thereof

Life of this patent

Anti-ceacam5 antibodies and uses thereof

Life of this patent

Abstract

Claims8